Introduction and Objective: Diabetes mellitus is a common complication after solid organ transplant (SOT). Sodium-glucose cotransporter inhibitors (SGLT2i) have shown significant cardio-renal benefits in people with type 2 diabetes. However, their use in SOT recipients remains underexplored in the existing literature. We aimed to perform a systematic review and meta-analysis to evaluate the efficacy and […]
Read MoreMonth: July 2025
742-P: Impact of Virtual Patient Simulation on Improving T2D Diagnosis and Management
Introduction and Objective: This study examines the impact of online, virtual patient simulation (VPS)-based continuing medical education (CME) on performance related to diagnosis and management of T2D by diabetologists/endocrinologists (D/Es) and primary care physicians (PCPs).Methods: Intervention was 2 patient scenarios presenting in a VPS. Clinical guidance (CG) based on evidence was provided following each decision, […]
Read More896-P: Positive Effect of Acute and Chronic Effects of Oral Ketones in Subjects with HFrEF and Diabetes
Introduction and Objective: Ketones are energy substrates, serving as a “superfuel” for the heart, skeletal muscle, etc.. Our previous work showed that 3-hour intravenous (IV) exogenous ketones (KE) improved left ventricular function in T2D patients with HFrEF by up to 6%, dose-dependently. However, IV delivery is invasive and impractical for daily use. This study explores […]
Read More1532-P: Alternative Polyadenylation in Key Metabolic Tissues from Individuals with Type 2 Diabetes
Introduction and Objective: Type 2 diabetes (T2D) is marked by impaired insulin secretion and action in metabolic organs like adipose tissue and skeletal muscle. Aberrant gene expression contributes to T2D. Alternative polyadenylation (APA) alters gene expression by producing mRNA isoforms with variable 3’ UTR lengths. The 3’ UTR interacts with trans-factors, affecting mRNA stability, translation, […]
Read More895-P: Proximal Intestinal Mucosal Ablation (PIMA) Eliminates the Need for Exogenous Insulin in Type 2 Diabetes—Initial STEAM-IE Trial Results
Introduction and Objective: Proximal Intestinal Mucosal Ablation (PIMA) is a new endoscopic procedure to treat type 2 diabetes (T2D). PIMA replicates the metabolic benefits of gastric bypass surgery by ablating up to 75 cm of the post-ampullary intestinal mucosa with radiofrequency vapor ablation (RFVA). Similar technologies, limited to 15cm of duodenal mucosa, have attempted to […]
Read More1383-P: Association of Liver Health Metrics and Demographic Parameters in Type 2 Diabetes and Obesity—Insights from a Multiregional Indian Cohort
Introduction and Objective: Type 2 diabetes (T2D) is frequently associated with hepatic complications like fatty liver and fibrosis named Metabolic dysfunction associated steatotic liver disease (MASLD).This study evaluates the demographic profile, Body Mass Index (BMI) and liver health parameters— Fibrosis-4 (FIB-4) score, Controlled Attenuation Parameter (CAP) score and Liver Stiffness Measurement (LSM)Methods: A total of […]
Read More894-P: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist
Introduction and Objective: MET-233 is an ultra-long acting (ULA) amylin analog being evaluated in clinical trials for the treatment of obesity. We sought preclinical proof of concept that MET-233, designed to be combined with GLP-1R agonist MET-097, is an effective candidate for obesity treatment.Methods: MET-233 emerged from an amylin analog development program focused on potency, […]
Read More1143-P: Evaluating an Evidence-Based Quality Improvement Initiative for Food Insecurity Screening and Referral in Adults with Diabetes Initiating Continuous Glucose Monitor Therapy
Introduction and Objective: This study evaluated the prevalence of food insecurity (FI) among adults with diabetes initiating continuous glucose monitoring (CGM) therapy compared to national averages and examined associations with gender, age, and glycemic outcomes.Methods: Fifty adults initiating CGM therapy were screened for FI using the USDA Six-Item Short Form. Individuals with an FI score […]
Read More893-P: Long-Term Administration of Dorzagliatin Combined with Sitagliptin for the Management of Glucose Homeostasis in High-Fat Diet–Induced Obesity Mice
Introduction and Objective: A short-term study in obese T2D patients showed that the combination of dorzagliatin, a glucokinase activator (GKA) and sitagliptin improved glucose controls with increased GLP-1 secretion. This study aims to assess the impact of long-term administration of dorzagliatin and the combination of dorzagliatin/sitagliptin on glucose homeostasis in high-fat diet-induced obesity/diabetes (DIO) mice.Methods: […]
Read More851-P: A Phase 1, Double-Blind, Placebo-Controlled Single- and Multiple-Ascending Dose Study of the Novel Lipidated IL-22 Receptor Agonist CK-0045 in Adults with and without Obesity
Introduction and Objective: CK-0045 is a novel long-acting IL-22 receptor agonist with great potential for treatment of patients with metabolic diseases based on preclinical data. Here we present the results of a randomized, double-blind, placebo-controlled, Phase 1 study investigating safety, tolerability, and pharmacokinetics of CK-0045 in healthy participants with and without obesity.Methods: A total of […]
Read More